June 13, 2011
Otsuka Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Otsuka Announces Initiation of Phase I Clinical Trial for Therapeutic
Cancer Vaccine OCV-105
Tokyo, Japan, June 13, 2011 -- Otsuka Pharmaceutical Co., Ltd. today announced the initiation of the phase I clinical trial of OCV-105 for pancreatic cancer in Japan. OCV-105 is a potential therapeutic cancer vaccine which has been co-developed by OncoTherapy Science, Inc. and Otsuka Pharmaceutical.
OCV-105 is a therapeutic cancer vaccine targeting the tumor specific antigen which is highly expressed with high frequency for pancreatic cancer. It is expected that OCV-105 suppresses the growth and progress of pancreatic cancer by the induction and activation of cytotoxic T-cells which directly damage pancreatic cancer cells.
The phase I clinical trial will evaluate the safety of OCV-105 in patients with pancreatic cancer refractory to or intolerance to the standard therapy.
Based on its corporate philosophy of 'Otsuka-people creating new products for better health worldwide,' Otsuka Pharmaceutical is dedicated to contributing to the health of people around the world.
Information in this news release was current as of the original release date.